IB-MECA, an Adenosine A3 Receptor Agonist, Does not Influence Survival of Lethally
γ-irradiated Mice

Michal Hofer1, Milan Pospíšil1, Ladislav Dušek2, Zuzana Hoferová1, Denisa Komůrková1

1Laboratory of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of
Sciences of the Czech Republic, Královopolská 135, CZ-61265 Brno, Czech Republic;
2Institute of Biostatistics and Analyses, Masaryk University, Kamenice 126/3, CZ-62500
Brno, Czech Republic

Corresponding author: M. Hofer, Laboratory of Experimental Hematology, Institute of
Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Královopolská 135, CZ-
61265 Brno, Czech Republic. E-mail: hofer@ibp.cz

Short title: Lethal γ-irradiation and adenosine A3 receptor agonist
Summary

In our previous studies, IB-MECA, an adenosine A3 receptor agonist, was found to stimulate proliferation of hematopoietic progenitor and precursor cells in mice. This property of IB-MECA was considered to be responsible for its ability to support regeneration of suppressed hematopoiesis after irradiation with sublethal doses of γ-rays when the drug was given in a post-irradiation treatment regimen. This study was aimed at assessing the ability of IB-MECA to influence a 30-day survival of lethally irradiated mice. In a series of experiments, IB-MECA was administered following various lethal radiation doses in various numbers of drug doses and various administration routes. Though in some of these experiments a moderate increase in 30-day survival was observed in IB-MECA-treated mice, the differences in comparison with the controls were not significantly different. It can be inferred from these results and those of previous studies assessing the effects of IB-MECA after sublethal radiation doses that IB-MECA can probably influence only a substantially preserved hematopoiesis like that remaining after sublethal irradiation. Future studies should be aimed at evaluation of the abilities of IB-MECA to influence post-irradiation survival when administered as a part of combined treatment regimens.

Key words: Mouse - IB-MECA - Adenosine A3 receptor agonist - Lethal γ-irradiation - Survival

The topic “Therapeutic agents (postexposure treatment)” with the objective “To develop new therapeutic agents that can be used to treat people who have been exposed to ionizing radiation” was given a top priority among research areas for radiological nuclear threat countermeasures (Pellmar et al. 2005).
Adenosine, a naturally occurring nucleoside, was found to play a regulatory role in many organ systems in the mammals by acting on cell membrane receptors. It was stated that the regulatory activities of adenosine represented a universal intercellular communication system (Abbracchio 1996) and that adenosine was a primordial signaling molecule modulating physiological responses in all mammalian tissues (Linden 2001). Up to date four subtypes of adenosine membrane receptors were described, namely A\(_1\), A\(_2a\), A\(_2b\), and A\(_3\). Activation of adenosine receptors can be achieved either non-selectively, by adenosine, an endogenous agonist, or selectively by the use of various adenosine analogs which exhibit different degrees of receptor specificity (Abbracchio and Burnstock 1998, Klotz 2000).

In experimental studies on hematopoiesis, a non-selective adenosine receptor activation, achieved by a combination of adenosine monophosphate, an adenosine prodrug, and dipyridamole, a drug inhibiting the cellular uptake of adenosine, was found to stimulate regeneration from radiation-induced myelosuppression (Pospíšil et al. 1992, 1993, 1995, 1998, Hofer et al. 1997, 1999, 2002). The non-selective activation of adenosine receptors was found to induce also an increased survival of lethally irradiated mice (Pospíšil et al. 1993, 1995).

Further hematological investigations were carried out using synthetic adenosine analogs, more or less specific for the individual receptor subtypes. \(N^6\)-(3-iodobenzyl)adenosine-5’-N-methyluronamide (IB-MECA), a selective agonist of the adenosine A\(_3\) receptors, was observed to stimulate proliferation of hematopoietic progenitor cells for granulocytes/macrophages and erythrocytes (Pospíšil et al. 2004). IB-MECA was reported to positively influence the recovery from myelosuppression evoked by anti-cancer chemotherapy (Fishman et al. 2000, 2001, Bar-Yehuda et al. 2002, Hofer et al. 2006) and to act, together with \(N^6\)-cyclopentyladenosine (CPA), an A\(_1\)-selective adenosine receptor agonist, homeostatically in hematopoietic tissue during the phases of cell depletion and
regeneration (Hofer et al. 2007, 2008). Moreover, adenosine A₃ receptor has been localized on hematopoietic precursor cells (Štreitová et al. 2010) and has been found to be expressed in premyelocytic cells in dependence on the cell cycle phase (Hofer et al. 2011a).

Hematopoiesis-stimulating abilities of selective activation of adenosine A₃ receptors were confirmed also in studies in which suppression of hematopoiesis was experimentally induced by ionizing radiation. After exposing mice to a sublethal dose of 4 Gy of γ-rays, IB-MECA administered in a therapeutic regimen on days 1 and 2 after irradiation was found to significantly increase important hematopoietic parameters (Hofer et al. 2010, 2011b).

Until now no studies were performed concerning the ability of IB-MECA to influence survival of experimental animals following their exposure to lethal radiation doses. Such studies would supplement the existing knowledge about mechanisms of action of IB-MECA in an irradiated mammalian organism and would be important also from the practical point of view – in determination of the extent of radiation doses which would represent indication for contingent therapeutic approach using an adenosine A₃ receptor agonist. We have tried to fill in this gap by experiments whose results are presented in this communication.

B10CBAF₁ male mice aged 3 months and weighing in average 30 g were obtained from the breeding facility of the Medical Faculty, Masaryk University, Brno, Czech Republic. The mice were kept under controlled conditions; standardized pelleted diet and HCl-treated tap water were available at libitum. The use and treatment of the animals followed the European Community Guidelines as accepted principles for the use of experimental animals. The experiments were carried out with the approval of the Institute’s Ethical Committee.

The mice were whole-body irradiated at the dose rate of 0.15 Gy/min using a γ-ray source (⁶⁰Co, Chisostat, Chirana, Praha, Czech Republic).

$N^6$-(3-iodobenzyl)adenosine-5’-N-methyluronamide (IB-MECA, Sigma, St. Louis, MO, USA) was dissolved initially in dimethyl sulfoxide, diluted in sterile saline, and
administered i.p. or p.o. in various post-irradiation (i.e., therapeutic) treatment regimens. The final concentration of dimethyl sulfoxide per one dose was always 2%. DMSO itself was shown to have radioprotective effects (e.g., Chapman et al. 1979). Therefore, pertinent solvents containing 2% DMSO concentration were used for control interventions.

Survival was recorded daily up to day 30 after irradiation. Analysis of survival time was carried out by Kaplan-Meier methodology; estimates of mean survival time were derived from the Kaplan-Meier curve. Differences in mean survival time between IB-MECA-treated and control mice were tested by a log-rank test. Differences in 30-day survival between IB-MECA-treated and control mice were tested by Fisher’s exact test or maximum likelihood chi-square test (in experiment 5). The significance level was set at P < 0.05.

Five experiments employing various radiation doses and various IB-MECA treatment regimens have been performed in total (1 – 5).

1) **IB-MECA administered i.p. (105 μg/kg per dose) on days 1 and 2 after irradiation with the dose of 9 Gy**: In this experiment the mice were irradiated with a nearly absolutely lethal γ-ray dose of 9 Gy. The dosing and timing of IB-MECA was identical with that previously found to positively influence the recovery of hematopoiesis after an exposure to a sublethal radiation dose (Hofer et al. 2010, 2011b).

2) **IB-MECA administered i.p. (105 μg/kg per dose) on days 1 and 2 after irradiation with the dose of 8 Gy**: This survival study comprised the same pharmacological treatment regimen with IB-MECA and exposure of the mice to an approximately mid-lethal radiation dose.

3) **IB-MECA administered i.p. (105 μg/kg per dose) on days 6, 7, 8, and 9 after irradiation with the dose of 8.5 Gy**: The timing of administration of IB-MECA in this experiment was shifted to later post-irradiation time intervals (day 6 to day 10) with the aim to affect the phase of recovery of the hematopoietic tissues.
4) **IB-MECA administered p.o. (105 μg/kg per dose) on days 1, 2, 3, 4, 5, 6, 7, 8, and 9 after irradiation with the dose of 9 Gy**: A prolonged 9-day post-irradiation treatment regimen with IB-MECA administered perorally was also the object of our attention.

5) **IB-MECA administered i.p. (500 μg/kg per dose) on days 1 and 2 after irradiation with the dose of 8.5 Gy**: In this experiment, effects of high doses of IB-MECA, which can be expected to evoke also a non-selective activation of adenosine receptors, were evaluated.

The results of the experiments are summarized in Table 1 (numbers of mice surviving by day 30 after irradiation) and Table 2 (mean survival times after irradiation). Different percentages of surviving and died mice after a radiation dose of 8.5 Gy were obtained in experiment 3 and 5. Since the described studies were done in the course of the whole year, seasonal variations can be responsible for the observed differences. Another explanation of this finding may consist of differing actions of various numbers of injections and their timings.

Taken together, the results on survival of experimental mice administered the agonist of adenosine A3 receptors IB-MECA in a variety of post-irradiation (therapeutical) treatment regimens following the exposure of the mice to various lethal doses of γ-rays show that IB-MECA does not significantly modulate this parameter. Both scientific and practical importance of these findings consists in their joint evaluation with previously published results on the stimulatory action of IB-MECA on hematopoiesis in sublethally γ-irradiated mice (Hofer et al. 2010, 2011b). The reason for seemingly contradictory findings of radiation recovery-supporting effects of IB-MECA in sublethally irradiated mice and its ineffectiveness in lethally irradiated ones lies probably in the mechanisms by which IB-MECA influences the consequences of irradiation. If the positive action of IB-MECA in the irradiated mammalian organism is concentrated on the stimulation of hematopoietic progenitor and precursor cells, as follows not only from radiation experiments (Hofer et al. 2010, 2011b) but as supported
also by the results of other hematological studies (Pospíšil et al. 2004, Fishman et al. 2000, 2001, Bar-Yehuda et al. 2002, Hofer et al. 2006, 2007, 2008), it can be assumed that there remain too few hematopoietic progenitor and precursor cells after a lethal irradiation to enable an effective employment of the hemopoiesis-stimulating properties of IB-MECA. Thus, when taking into account all results on the effects of IB-MECA in irradiated mice, IB-MECA can, in our opinion, be considered a promising drug for the treatment of the bone marrow radiation syndrome.

In all experimental groups of mice administered IB-MECA in the experiments reported here, survival of IB-MECA-treated mice was always the same or slightly better than that in the controls, with the only exception of mice repeatedly administered a high IB-MECA dose of 500 μg/kg. It can be deduced from this finding that administration of IB-MECA was not accompanied by undesirable side effects which can be clinically important in the conditions of a serious irradiation. Thus, even if IB-MECA was administered in association with higher radiation doses than those after which it could be expected to be most effective, its administration would highly probably be not accompanied with undesirable side effects. In human studies, CF-101, a commercial preparation of IB-MECA, was found to be safe and well tolerated (van Troostenburg et al. 2004, Bar-Yehuda et al. 2007). Therefore, IB-MECA can, in our opinion, be incorporated into the spectrum of agents suitable for treating radiation damage in humans.

**Conflict of Interest**

There is no conflict of interest.
Acknowledgements

This work was supported by the Ministry of Defense of the Czech Republic [project "Receptor", project number 1001 8 5090] and by the Grant Agency of the Czech Republic [grant numbers 305/08/0158 and P303/11/0128].

References

ABBRACCHIO MP: P1 and P2 receptors in cell growth and differentiation. Drug Dev Res 39: 393-406, 1996.

ABBRACCHIO MP, BURNSTOCK G: Purinergic signalling: Pathophysiological roles. Jap J Pharmacol 78: 113-145, 1998.

BAR-YEHUDA S, MADI L, BARAK D, MITTELMAN M, ARDON E, OCHAION A, COHN S, FISHMAN P: Agonists of the A3 adenosine receptor induce G-CSF production via NF-κB activation: A new class of myeloprotective agents. Exp Hematol 30: 1390-1398, 2002.

BAR-YEHUDA S, SILVERMAN MH, KERNS WD, OCHAION A, COHEN S, FISHMAN P: The anti-inflammatory effect of A3 adenosine receptor agonist: a novel targeted therapy for rheumatoid arthritis. Expert Opin Invest Drugs 16: 1601-1613, 2007.

CHAPMAN JD, DOERN SD, REUVERS AP, GILLESPIE CJ, CHATTERJEE A, BLAKELEY EA, SMITH KC, TOBIAS CA: Radioprotection by DMSO of mammalian cells exposed to X-rays and to heavy charged particle beams. Radiat Environ Biophys 16: 29-41, 1979.

FISHMAN P, BAR-YEHUDA S, BARER F, MADI L, MULTANI AS, PATHAK S: The A3 adenosine receptors as a new target for cancer therapy and chemoprotection. Exp Cell Res 269: 230-236, 2001.
FISHMAN P, BAR-YEHUDA S, FARBSTEIN T, BARER F, OHANA G: Adenosine acts as a chemoprotective agent by stimulating G-CSF production. A role for A<sub>1</sub> and A<sub>3</sub> receptors. *J Cell Physiol* **183**: 393-398, 2000.

HOFER M, DUŠEK L, HOFEROVÁ Z, STIXOVÁ L, POSPÍŠIL M: Expression of mRNA for adenosine A<sub>1</sub>, A<sub>2a</sub>, A<sub>2b</sub>, and A<sub>3</sub> receptors in HL-60 cells: Dependence on cell cycle phases. *Physiol Res* **60**: 913-920, 2011a.

HOFER M, POSPÍŠIL M, DUŠEK L, HOFEROVÁ Z: Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A<sub>3</sub> receptor agonist on hematopoiesis in sublethally γ-irradiated mice. *Biomed Pharmacother* **65**: 427-431, 2011b.

HOFER M, POSPÍŠIL M, NETÍKOVÁ J, ZNOJIL V, VÁCHA J: Enhancement of haemopoietic spleen colony formation by drugs elevating extracellular adenosine. Effects of repeated in vivo treatment. *Physiol Res* **46**: 285-290, 1997.

HOFER M, POSPÍŠIL M, NETÍKOVÁ J, ZNOJIL V, VÁCHA J: Granulocyte colony-stimulating factor and drugs elevating extracellular adenosine act additively to enhance haematopoietic spleen colony formation in irradiated mice. *Physiol Res* **48**: 37-42, 1999.

HOFER M, POSPÍŠIL M, ŠEFC L, DUŠEK L, VACEK A, HOLÁ J, HOFEROVÁ Z, ŠTREITOVÁ D: Activation of adenosine A<sub>3</sub> receptors supports hematopoiesis-stimulating effects of granulocyte colony-stimulating factor in sublethally irradiated mice. *Int J Radiat Biol* **86**: 649-656, 2010.

HOFER M, POSPÍŠIL M, VACEK A, HOLÁ J, ZNOJIL V, WEITEROVÁ L, ŠTREITOVÁ D (2006) Effects of adenosine A<sub>3</sub> receptor agonist on bone marrow granulocytic system in 5-fluorouracil-treated mice. Eur J Pharmacol 538: 163-167.

HOFER M, POSPÍŠIL M, ZNOJIL V, HOLÁ J, ŠTREITOVÁ D, VACEK A: Homeostatic action of adenosine A<sub>3</sub> and A<sub>1</sub> receptor agonists on proliferation of hematopoietic precursor cells. *Exp Biol Med* **233**: 897-900, 2008.
HOFER M, POSPÍŠIL M, ZNOJIL V, HOLÁ J, VACEK A, ŠTREITOVÁ D: Adenosine A3 receptor agonist acts as a homeostatic regulator of bone marrow hematopoiesis. *Biomed Pharmacother* **61**: 356-359, 2007.

HOFER M, POSPÍŠIL M, ZNOJIL V, VACEK A, WEITEROVÁ L, HOLÁ J, VÁCHA J: Drugs elevating extracellular adenosine promote regeneration of haematopoietic progenitor cells in severely myelosuppressed mice: their comparison and joint effects with granulocyte colony-stimulating factor. *Eur J Haematol* **68**: 4-11, 2002.

KLOTZ K-N: Adenosine receptors and their ligands. *Naunyn-Schmied Arch Pharmacol* **362**: 382-391, 2000.

LINDEN J: Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. *Annu Rev Pharmacol Toxicol* **41**: 775-778, 2001.

PELLMAR TC, ROCKWELL S, and the Radiological/Nuclear Threat Countermeasures Working Group: Priority list of research areas for radiological nuclear threat countermeasures. *Radiat Res* **163**: 115-123, 2005.

POSPÍŠIL M, HOFER M, NETÍKOVA J, PIPALOVÁ I, VACEK A, BARTONÍČKOVA A, VOLENEC K: Elevation of extracellular adenosine induces radioprotective effects in mice. *Radiat Res* **134**: 323-330, 1993.

POSPÍŠIL M, HOFER M, NETÍKOVA J, VIKLICKÁ Š, PIPALOVÁ I, BARTONÍČKOVA A: Effect of dipyridamole and adenosine monophosphate on cell proliferation in the hemopoietic tissue of normal and gamma-irradiated mice. *Experientia* **48**: 253-257, 1992.

POSPÍŠIL M, HOFER M, VACEK A, ZNOJIL V, PIPALOVÁ I: Effects of stable adenosine receptor agonists on bone marrow haematopoietic cells as inferred from the cytotoxic action of 5-fluorouracil. *Physiol Res* **53**: 549-556, 2004.

POSPÍŠIL M, HOFER M, ZNOJIL V, NETÍKOVA J, VÁCHA J, HOLÁ J, VACEK A: Granulocyte colony-stimulating factor and drugs elevating extracellular adenosine
synergize to enhance haematopoietic reconstitution in irradiated mice. *Eur J Haematol* **60**: 172-180, 1998.

POSPÍŠIL M, HOFER M, ZNOJIL V, VÁCHA J, NETÍKOVA J, HOLÁ J: Radioprotection of mouse hemopoiesis by dipyridamole and adenosine monophosphate in fractionated treatment. *Radiat Res* **142**: 16-22, 1995.

ŠTREITOVA D, ŠEFC L, SAVVULIDI F, POSPÍŠIL M, HOLÁ J, HOFER M: Adenosine A₁, A₂a, A₂b, and A₃ receptors in hematopoiesis. 1. Expression of receptor mRNA in four mouse hematopoietic precursor cells. *Physiol Res* **59**: 133-137, 2010.

VAN TROOSTENBURG A-R, CLARK EV, CAREY WOH, WARRINGTON SJ, KERNS, WD, COHN I, SILVERMAN MH, BAR-YEHUDA S, FONMG K-LL, FISHMAN P: Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A₃ adenosine receptor agonist, in healthy young men. *Int J Clin Pharmacol Therap* **42**: 534-542, 2004.
| Experiment | Radiation dose | Drug administration route | Control | N=3 (20.0%) | N=12 (80.0%) | p-value* |
|------------|----------------|----------------------------|---------|-------------|-------------|----------|
| Experiment 1 | 9 Gy, i.p. | | 15 | N=3 (20.0%) | N=12 (80.0%) | 0.999 |
| IB-MECA | 15 | N=3 (20.0%) | N=12 (80.0%) |
| Experiment 2 | 8 Gy, i.p. | | 10 | N=6 (60.0%) | N=4 (40.0%) | 0.628 |
| Control | 10 | N=8 (80.0%) | N=2 (20.0%) |
| IB-MECA | 10 | N=8 (80.0%) | N=2 (20.0%) |
| Experiment 3 | 8.5 Gy, i.p. | | 30 | N=5 (16.7%) | N=25 (83.3%) | 0.999 |
| Control | 30 | N=5 (16.7%) | N=25 (83.3%) |
| IB-MECA | 30 | N=5 (16.7%) | N=25 (83.3%) |
| Experiment 4 | 9 Gy, p.o. | | 20 | N=2 (10.0%) | N=18 (90.0%) | 0.999 |
| Control | 20 | N=3 (15.0%) | N=17 (85.0%) |
| IB-MECA | 20 | N=3 (15.0%) | N=17 (85.0%) |
| Experiment 5 | 8.5 Gy, i.p. | | 18 | N = 6 (33.3 %) | N = 12 (66.7%) | | |
| IB-MECA | 150 μg/kg | 21 | N = 8 (38.1 %) | N = 13 (61.9 %) | 0.807 |
| IB-MECA | 500 μg/kg | 21 | N = 6 (28.6 %) | N = 15 (71.4 %) |

* Fisher exact test or Maximum likelihood chi-square test (in experiment 5)
## Table 2 Mean survival times of mice after irradiation

|                | N  | Mean survival time (days) | p-value* |
|----------------|----|---------------------------|----------|
| **Experiment 1** |    |                           |          |
| radiation dose 9 Gy, drug administration route i.p. |    |                           |          |
| Control        | 15 | 17.9                      | 0.760    |
| IB-MECA        | 15 | 18.9                      |          |
| **Experiment 2** |    |                           |          |
| radiation dose 8 Gy, drug administration route i.p. |    |                           |          |
| Control        | 10 | 23.7                      | 0.356    |
| IB-MECA        | 10 | 26.7                      |          |
| **Experiment 3** |    |                           |          |
| radiation dose 8.5 Gy, drug administration route i.p. |    |                           |          |
| Control        | 30 | 15.8                      | 0.994    |
| IB-MECA        | 30 | 15.8                      |          |
| **Experiment 4** |    |                           |          |
| radiation dose 9 Gy, drug administration route p.o. |    |                           |          |
| Control        | 20 | 12.8                      | 0.273    |
| IB-MECA        | 20 | 14.3                      |          |
| **Experiment 5** |    |                           |          |
| radiation dose 8.5 Gy, drug administration route i.p. |    |                           |          |
| Control        | 18 | 19.1                      |          |
| IB-MECA 150 μg /kg | 21 | 20.3                      | 0.819    |
| IB-MECA 500 μg /kg | 21 | 19.0                      |          |

* log rank test